Epigraph journal

Epigraph is the official newsletter of the International League Against Epilepsy’s membership. Complimentary to all members. No subscription required. Please send articles and news to Epigraph@ilae.org

Sign up to receive the Epigraph newsletter.

Latest from Epigraph

Forced changes and creative solutions: The pandemic’s effects on epilepsy research

Stylized image of brain and viruses. Links to: Information for researchers regarding COVID-19 and epilepsy

After nearly three months, some countries are opening while others grapple with the spread of COVID-19. What will the epilepsy research landscape look like in six months, a year, five years? Will the changes imposed by the pandemic lead to long-term shifts in how research is done? Has anything positive resulted from these unprecedented weeks?

Can community-based interventions help to close the epilepsy treatment gap?

A poster created during the initiative to make people aware that epilepsy is not contagious, and that treatment is available.

While community-based interventions for epilepsy must be tailored to the region’s needs and culture, they can inform and improve one another through careful data collection, common data elements and expanding the outcomes they study, according to a recent meta-analysis.

ILAE Journal Prizes

2020 ILAE Journal Prizes virtual symposium
This year for the first time, the ILAE Journal Prizes were presented in a virtual symposium. All five prize winners presented their papers, and Mike Sperling spoke on how to write a good paper. This Epigraph explores the motivations for each paper

Second-line therapy for status epilepticus: What’s the latest?

Brain image

Most clinical guidelines provide little information on efficacy and safety to guide the choice of second-line therapy for status epilepticus. As a result, treatment choices may be driven as much by habit, training and tradition as by evidence. What do the latest data show about second-line treatment effectiveness, and how can research move forward?